What Researchers Did
Researchers investigated whether hyperbaric oxygen therapy (HBOT) could reduce the activity of perianal fistulas in patients with Crohn's disease when used alongside standard medical treatments.
What They Found
Patients who received HBOT in addition to conventional therapy experienced significant clinical improvements, including an 81.8% improvement in Crohn's Disease Activity Index (CDAI) scores and a 54.5% clinical remission rate. These beneficial effects on disease activity and inflammation markers were statistically significant, lasted for at least 6 weeks after HBOT, and were still observed in a follow-up assessment approximately 9 months post-treatment.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study did not include a control group, which makes it challenging to definitively attribute all observed improvements solely to hyperbaric oxygen therapy.